Back to top

Image: Bigstock

Alnylam Pharmaceuticals, Inc.

Read MoreHide Full Article

Alnylam is a development-stage biopharmaceutical company focused on the development of RNAi-based therapeutics. The company expects to achieve the profile of three marketed products by the end of 2020. Investor focus should be on the company's progress with its two late-stage pipeline candidates – patisiran and revusiran. Meanwhile, Alnylam’s RNAi technology has allowed the company to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals will not only provide it with funds but also take its RNAi technology outside the core focus area. However, any hiccup in the development/regulatory process of patisiran and revusiran will weigh heavily on the stock, given that the rest of its pipeline is mostly early-to-mid stage in nature. Its dependence on collaborations for revenues and pipeline development is also concerning.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Alnylam Pharmaceuticals, Inc. (ALNY) - free report >>

Published in